Orally administered, Emothion® is clinically effective in increasing GSH in humans
DESIO, Italy - August 16th, 2018
The clinical efficacy and pharmacokinetic profile of Emothion® - the S-Acetyl Glutathione (SAG) produced by Gnosis - have been evaluated in a human randomised, open-label, two-sequence, two-period, cross-over bioavailability study, versus a qualified reference product of glutathione (GSH).
The above study, published by a scientific group of the Sapienza University of Rome (Fanelli et al., Int J Clin Nutr Diet 2018), revealed a significant difference between Emothion® and the reference formulations both in terms of Cmax and AUC0-t of GSH in erythrocytes.
The study has a relevant significance because it is the first one testing the impact of the administration of the S-Acetyl Glutathione as a prodrug (Emothion®) on GSH levels in plasma and erythrocytes in humans.
SAG was not quantifiable in any plasma sample. This result shows that deacetylation of SAG occurs rapidly after its administration and that the whole amount of the substance is transformed into GSH before reaching the blood stream.
About Emothion® - S-Acetyl Glutathione
EMOTHION® is the crystalline form of S-Acetyl Glutathione, with a rapid dissolution rate and therefore it is orally well absorbed.
EMOTHION® is a precursor of glutathione and works as a GSH-replenishment agent.
For more information, visit https://www.gnosis-bio.com/emothion